TKI is named as an intervention in 6 current clinical trials in our China and India registers. 6 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Tata Memorial Hospital (1). The most-studied condition is Hepatocellular Carcinoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC
NCT05277844 · ClinicalTrials.gov ↗ · Oligometastatic Disease, Non-small Cell Lung Cancer, Driver Mutation
|
Phase 2 | Recruiting | Tata Memorial Hospital | India |
|
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
NCT06145308 · ClinicalTrials.gov ↗ · Salivary Gland Carcinoma, Precision Therapy
|
Phase 2 | Recruiting | Peking Union Medical College | China |
|
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
NCT07328009 · ClinicalTrials.gov ↗ · Hepato Cellular Carcinoma (HCC)
|
Phase 2 | Recruiting | Fudan University | China |
|
PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
NCT07463248 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)
|
Phase 2 | Recruiting | Wang Xin | China |
|
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
NCT07479485 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
|
Phase 1/2 | Recruiting | Lepu Biopharma Co., Ltd. | China |
|
Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
NCT06363006 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
|
Phase 1 | Recruiting | Peking Union Medical College Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Tata Memorial Hospital | 1 |
| Fudan University | 1 |
| Peking Union Medical College | 1 |
| Peking Union Medical College Hospital | 1 |
| Lepu Biopharma Co., Ltd. | 1 |
| Wang Xin | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 5 | 5 |
| Clinical trials in India | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
6 current trials in our China and India registers name TKI as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 6 of the 6 trials are recruiting: 5 with sites in China and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Tata Memorial Hospital (1), Fudan University (1), Peking Union Medical College (1) and Peking Union Medical College Hospital (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how TKI works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how TKI works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists TKI (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.